Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.46 |
| ▸ | LOX | P28300 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147946 | 0.89 | HTR6 (0.50) | HTR6LOXL2LOXMAOAALDH1A1 | |
| SCHEMBL3086452 | 0.87 | HTR6 (0.45) | HTR6LOXL2LOXMAOAKCNH2 | |
| SCHEMBL4210036 | 0.81 | CASP6 (0.51) | ALDH1A1POLBMAPT | |
| SCHEMBL3097281 | 0.81 | HTR6 (0.43) | HTR6ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL13147952 | 0.81 | CYP1A2 (0.44) | HTR6ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL14344711 | 0.81 | CA2 (0.48) | HTR6MAPTAOC3 | |
| SCHEMBL3092580 | 0.80 | CA2 (0.50) | HTR6MAPT | |
| SCHEMBL3092172 | 0.79 | NQO2 (0.48) | HTR6ALDH1A1POLBMAPTSMN1; SMN2 | |
| SCHEMBL3086379 | 0.79 | CA2 (0.49) | HTR6MAPT | |
| SCHEMBL13147939 | 0.79 | HTR6 (0.47) | HTR6ALDH1A1POLBMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799797-B2 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2076489-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-07-08 | — | — | EP | disclosed |
| CN-101472885-A | Arylsulfonyl naphthalene derivatives and uses thereof | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| CN-101472883-A | Arylsulfonylamino tetralin derivatives and use thereof | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | CN | disclosed |
| US-7531577-B2 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2009-05-12 | — | — | US | disclosed |
| EP-2041079-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. Hoffmann-Roche AG (CH) | 2009-04-01 | — | — | EP | disclosed |
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-01-17 | — | — | US | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147763-A1 | ARYLSULFONYL NAPHTHALENE DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147762-A1 | ARYLSULFONAMIDYL TETRALIN DERIVATIVES AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015208-A1 | Arylsulfonamidyl tetralin derivatives and uses thereof | HTR6, TPH1, HTR1B | HTR6 1/4885LOXL2 2354/4885LOX 1368/4885 |
| US-20070293526-A1 | Arylsulfonyl naphthalene derivatives and uses thereof | ARSA, AR, SULT2A1 | HTR6 427/4885LOXL2 4574/4885LOX 4365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.